13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002038158
Total reported value
$217.4M
$217.4M
23 檔
36.2%
At the close of Q4 2025, NEXTBio Capital Management LP disclosed equity holdings valued at approximately $217.4M, spread across 23 reported holdings.
During Q4 2025, NEXTBio Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 13.06% | -14.80% | EXIT | |
| 2 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 11.76% | +1.13% | — | |
| 3 | VOR | Vor Biopharma Inc | Stock-Other | 7.67% | -0.75% | — | |
| 4 | ZBIO | Zenas Biopharma Inc | Stock-Other | 6.86% | +1.11% | — | |
| 5 | STTK | Shattuck Labs Inc | Stock-Other | 6.74% | +2.50% | — | |
| 6 | VSTM | Verastem Inc | Stock-Other | 5.92% | -0.92% | — | |
| 7 | PVLA | Palvella Therapeutics Inc | Stock-Other | 5.08% | +1.53% | — | |
| 8 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.83% | +0.14% | — | |
| 9 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.24% | +1.64% | — | |
| 10 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.85% | +4.73% | — | |
| 11 | IVA | Inventiva SA - Adr | Stock-Other | 3.54% | -0.33% | — | |
| 12 | CMPX | Compass Therapeutics Inc | Stock-Other | 3.51% | -2.08% | EXIT | |
| 13 | CMPS | Compass Pathways PLC | Stock-Other | 3.05% | +6.37% | — | |
| 14 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.95% | +0.44% | — | |
| 15 | ✓ | Crescent Biopharma Inc. | Stock-Other | 2.59% | -0.09% | — | |
| 16 | PCVX | Vaxcyte Inc | Stock-Other | 2.58% | +0.30% | — | |
| 17 | EVMN | Evommune Inc | Stock-Other | 2.29% | -1.23% | — | |
| 18 | COGT | Cogent Biosciences Inc | Stock-Other | 2.00% | -0.01% | — | |
| 19 | IRON | Disc Medicine Inc | Stock-Other | 1.99% | +0.21% | — | |
| 20 | OCS | Oculis Holding AG | Stock-Other | 1.75% | -1.85% | EXIT | |
| 21 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.69% | — | — | |
| 22 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.25% | -1.23% | EXIT | |
| 23 | ACET | Adicet Bio Inc | Stock-Other | 0.78% | +0.13% | — |
According to official SEC Form 13F filings, NEXTBio Capital Management LP reported a total U.S. public equity portfolio value of $217.4M across 23 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including 430, PTGX, VOR) accounted for 36.2% of total reported equity market value during Q4 2025.
During Q4 2025, NEXTBio Capital Management LP's top holdings by market value included 430 (13.1%)、PTGX (11.8%)、VOR (7.7%). The largest single position, 430, represented 13.1% of total portfolio value.
In Q4 2025, NEXTBio Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.